X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

CGTX

Closed

Cognition Therapeutics Inc

0.3123
+0.0025 (+0.81%)
Last Update: 01 Jul 2025 23:04:00
Yesterday: 0.3098
Day's Range: 0.2933 - 0.314
Send
When Written:
 
1.98
Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing new treatments for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, CT1812, is a small molecule compound that targets the toxic oligomers of beta-amyloid, a protein that accumulates in the brains of Alzheimer's patients. CT1812 has shown promising results in preclinical studies and early-stage clinical trials, and is currently being evaluated in a Phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease. Cognition Therapeutics was founded in 2007 and is headquartered in Pittsburgh, Pennsylvania.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X